{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "EPRX",
  "name": "Eupraxia Pharmaceuticals Inc.",
  "url": "https://frontierpicks.com/dossiers/EPRX/",
  "json_url": "https://frontierpicks.com/dossiers/EPRX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Eupraxia Pharmaceuticals' once-a-year EoE steroid injection, EP-104GI, is priced on open-label remission data from 14 patients. The December 2026 placebo-controlled Phase 2b interim, fully enrolled at 120 patients, settles the case.",
  "invalidation_trigger": "A weekly close below $6.00, a round level under the $6.62 close of 2026-10-16 that would extend the slide from the $9.10 52-week high. A December 2026 Phase 2b interim that fails to separate EP-104GI from placebo, or a slip past 2026-12-31 with no new date, would also end the case.",
  "catalyst_date": "2026-11-13",
  "pick": {
    "id": "P-2026-10-01-EPRX",
    "conviction": "MEDIUM",
    "status": "closed",
    "opened": "2026-10-01",
    "open_close": 7.83,
    "kill_level": 7,
    "kill_basis": "weekly",
    "horizon_end": "2026-12-31",
    "last_date": "2026-10-05",
    "last_close": 7.745,
    "return_pct": -1.09,
    "spy_return_pct": 1.42,
    "excess_pp": -2.5,
    "kill_distance_pct": null,
    "closed": "2026-10-05",
    "close_reason": "withdrawn",
    "outcome": "trailed",
    "scoreboard": "https://frontierpicks.com/track-record/"
  },
  "themes": [
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Eupraxia is a Canadian issuer listed on the Toronto Stock Exchange and Nasdaq; it files annual reports on Form 40-F and interim reports on Form 6-K rather than 10-K and 10-Q.",
    "At 2026-06-30 there were 1,428,571 pre-funded warrants with a nominal exercise price and 8.3M preferred shares outstanding, both relevant to the fully diluted share count.",
    "All published EP-104GI efficacy results are open-label, from cohorts of 3 to 19 patients; no placebo-controlled results have been reported."
  ],
  "source_links": [],
  "body_markdown": "## Current Thesis\n\nEupraxia Pharmaceuticals' once-a-year steroid injection for eosinophilic esophagitis (EoE), EP-104GI, is priced on open-label remission data from 14 patients. The December 2026 interim from the randomized, placebo-controlled Phase 2b portion of the RESOLVE trial, now fully enrolled at 120 patients, settles the case.\n\nThe shares closed at $6.83 on 2026-10-30 (adjusted daily closes). That is 24.9% below the $9.10 52-week high and 4.8% above the close three months earlier. The 14-day relative strength index, a momentum gauge, reads 44.1, up from 33.5 on 2026-10-16. The close sits below the $7.00 price of the company's February 2026 offering.\n\nThe company's 2026-09-30 release reported that 9 of 14 patients (64%) in cohorts 5–9 stayed in clinical remission 52 weeks after one dose. The top-dose cohort had 3 patients, and 2 stayed in remission. All published efficacy results are open-label, and no control-arm result exists yet.\n\nTwo items are new since the 2026-10-18 note. A 2026-10-23 headline reported that BB Biotech, a Swiss-listed biotech investment company, initiated a position. Neither item changes what the December interim will show.\n\nThe narrative is maturing: the durability story has been public since 2026-09-30, six firms cover it, and November brings presentations that restate it, not new efficacy data.\n\n## Bull Case\n\n- **The readout has its full sample.** The company announced on 2026-10-15 that the blinded Phase 2b portion reached 120 patients. The September 2025 plan called for at least 120 patients with a minimum of 40 per dose group, which gives the interim more weight than the 14-patient open-label set.\n- **Durability is the product claim.** Remission across cohorts 5–9 was 53% (10/19) at 12 weeks, 78% (14/18) at 24 weeks, 61% (11/18) at 36 weeks and 64% (9/14) at 52 weeks (company release, 2026-09-30). The comparison is daily oral budesonide (Takeda's Eohilia, approved February 2024) and weekly Dupixent injections (approved for EoE in May 2022).\n- **Safety fits local delivery.** The 2026-09-30 release reported no oral candidiasis, no adrenal insufficiency and no glucose abnormalities across all ten cohorts.\n- **Cash covers the readout.** At 2026-06-30 the company held $52.4M in cash and equivalents and $81.2M in short-term investments against a six-month net loss of $27.1M (H1 2026 interim statements, Form 6-K). It guides runway into the second half of 2028 (Q2 release, 2026-08-11).\n- **Analyst targets sit well above the price.** Vista Partners listed on 2026-10-02: Stifel Buy $25, Cantor Fitzgerald Overweight $19, Raymond James Strong Buy $18, Wedbush Outperform $17, Oppenheimer Outperform $17 and H.C. Wainwright Buy $11. H.C. Wainwright assigned an 85% probability of success on 2026-10-01 (Investing.com).\n- **A specialist investor has appeared.** A 2026-10-23 headline reported that BB Biotech initiated a position in the company.\n\n## Bear Case\n\n- **The efficacy sample is small.** The 52-week figure covers 14 patients and the top-dose cohort has 3. EoE symptom scores also move in placebo arms, and no EP-104GI result includes a control group.\n- **The shares gave back the data-release gain.** The 52-week high of $9.10 came with the 2026-09-30 release. The close was $7.24 on 2026-10-02 and $6.83 on 2026-10-30.\n- **Dilution is a recurring pattern.** The 2026-02-20 offering sold 7,607,145 shares at $7.00 plus 1,428,571 pre-funded warrants. At 2026-06-30 there were 65.5M shares outstanding and 8.3M preferred shares (H1 2026 interim statements).\n- **The primary endpoint is undisclosed.** The company's 2026-09-30 and 2026-10-15 releases give the December 2026 timing but no endpoint. The 2026-11-13 Analyst Day may or may not name it.\n- **The timing has no day attached.** The company guides \"December 2026\" only. A slip into 2027 would leave the case unresolved.\n\n## Setup & Price Structure\n\nThe adjusted close was $6.83 on 2026-10-30. That is 3.2% above the $6.62 close of 2026-10-16 and 24.9% below the $9.10 52-week high. The relative strength index of 44.1 is neither oversold nor stretched.\n\nThe shares trade below the $7.00 February offering price and below the $7.24 close of 2026-10-02. The $6.00 weekly-close level named in the previous note is 12.2% under the latest close. A 2026-10-2x web quote showing $5.97 could not be matched to the adjusted series, which is the reference here.\n\nCrowding evidence is thin. The shares are not extended above a rising moving average, and no insider selling or new issuance is on record since the previous note. The one crowding input is imminent event attention: a company-hosted Analyst Day on 2026-11-13, two conference appearances and a possible Q3 report in the same fortnight. The note's view is that November events restate known data. It is wrong if the company discloses new patients, an endpoint or a dose-response detail that moves the shares on its own.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-11-10, est.: Q3 2026 financial results.** The company has not announced a date. Earnings Whispers lists 2026-11-10; the prior note estimated ~2026-11-05 from last year's timing. The report updates cash and any change to interim timing.\n- **2026-11-10 to 2026-11-12: Stifel 2026 Healthcare Conference.** The 2026-10-22 company release lists participation; a secondary summary gives a fireside chat on 2026-11-10.\n- **2026-11-13: Virtual Analyst Day on EP-104GI in EoE, 8:30am ET.** Confirmed in the company's 2026-10-22 release. It is the main chance for disclosure of the interim design and endpoints.\n- **2026-11-16 to 2026-11-19: Jefferies Global Healthcare Conference, London.** The company presents on 2026-11-16 per its release.\n- **~2026-12-15, est.: Phase 2b interim from RESOLVE.** Just outside the window. The company guides \"December 2026\"; this is the event the case turns on.\n\n## What Would Change Our Mind\n\nThe case breaks if the December 2026 interim does not separate EP-104GI from placebo, or if the company moves the interim past 2026-12-31 without a new date. A Q3 report or Analyst Day that adds an equity raise before the readout would also weaken it, since the shares already trade below the $7.00 February offering price.\n\nOn price, a weekly close below $6.00 would extend the slide from the $9.10 high and break the case. A weekly close above the $7.24 close of 2026-10-02 would show the post-data selling has reversed, though it would not change what the interim shows.\n\n## Correlation Notes\n\nEPRX trades on its own trial timeline, not on a sector driver. Its readout depends on placebo response in EoE symptom scores, which is company-specific.\n\nRead-across comes from EoE competitors: Takeda's Eohilia and Regeneron and Sanofi's Dupixent set the efficacy bar. Small-cap biotech funding conditions affect any financing that follows the readout. No theme cluster currently includes the name.",
  "first_seen": "2026-09-30",
  "last_analyzed": "2026-10-31T08:07:38+00:00",
  "last_synthesized": "2026-10-31",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}